Table 1.
Comparisons of clinical characteristics between patients with final successful and unsuccessful liberation from MV
| Variable | Total (n=103) | Final liberation of MV |
P-value | |
|---|---|---|---|---|
| Successful (n=87) | Unsuccessful (n=16) | |||
| Age (yr) | 69 (22–87) | 69 (22–86) | 69 (45–87) | 0.912 |
| Male sex | 72 (69.9) | 60 (69.0) | 12 (75.0) | 0.771 |
| BMI (kg/m2) | 22.3 (13.8–37.6) | 23.0 (13.8–37.6) | 21.2 (16.5–24.6) | 0.004 |
| Charlson comorbidity index | 2 (0–7) | 2 (0–6) | 2 (0–7) | 0.069 |
| Severity of illness on day of ICU admission | ||||
| APACHE II score | 22 (10–37) | 22 (10–37) | 22 (11–36) | 0.927 |
| SOFA score | 8 (2–17) | 8 (3–17) | 7 (2–16) | 0.506 |
| Time between ICU admission and first SBT (day) | 5 (3–26) | 4 (3–21) | 5 (3–26) | 0.885 |
| Underlying disease | ||||
| Diabetes | 40 (38.8) | 37 (42.5) | 3 (18.8) | 0.096 |
| Hemato-oncologic disease | 27 (26.2) | 19 (21.8) | 8 (50.0) | 0.029 |
| Chronic heart diseasea | 25 (24.3) | 21 (24.1) | 4 (25.0) | >0.999 |
| Chronic lung diseaseb | 17 (16.5) | 16 (18.4) | 1 (6.3) | 0.462 |
| Neurologic diseasec | 16 (15.5) | 15 (17.2) | 1 (6.3) | 0.456 |
| Chronic kidney disease (including hemodialysis) | 10 (9.7) | 9 (10.3) | 1 (6.3) | >0.999 |
| Alimentary disease | 9 (8.7) | 8 (9.2) | 1 (6.3) | >0.999 |
| Chronic liver diseased | 7 (6.8) | 6 (6.9) | 1 (6.3) | >0.999 |
| Tracheostomy during ICU stay | 30 (29.1) | 20 (23.0) | 10 (62.5) | 0.003 |
| ICU mortality | 19 (18.4) | 9 (10.3) | 10 (62.5) | <0.001 |
| Hospital mortality | 29 (19.5) | 17 (19.5) | 12 (75.0) | <0.001 |
Values are presented as median (range) for continuous variables or number (%) for categorical variables. The Mann-Whitney U-test was used for comparison of continuous variables and the chi-square or Fisher exact test (for small numbers) were used to compare categorical variables.
MV: mechanical ventilation; BMI: body mass index; ICU: intensive care unit; APACHE: Acute Physiology and Chronic Health Evaluation; SOFA: Sequential Organ Failure Assessment; SBT: spontaneous breathing trial.
Chronic heart diseases included ischemic heart diseases, arrhythmia, and valvular heart diseases;
Chronic lung diseases include chronic obstructive pulmonary diseases, asthma, and tuberculosis-destroyed lung;
Neurologic diseases included stroke, neuromuscular diseases, and neurodegenerative diseases;
Chronic liver diseases included hepatocellular carcinoma and liver cirrhosis.